Leadartis SL
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Leadartis SL - overview
Established
2013
Location
Madrid, -, Spain
Primary Industry
Biotechnology
About
Based in Madrid, Spain, and founded in 2013, Leadartis SL operates as a biopharmaceutical company that develops immunomodulatory therapies against cancer. In December 2023, the firm raised EUR 1. 6 million in venture funding led by investors Clave Capital, Sodena, and Capital Cell. The firm as of January 2023, has offices in Madrid and Noáin, Spain, and is led by its founder and CEO, Juan J.
Pérez Villar. The company engages in the generation of therapeutic antibodies called Trimerbodies, which target bispecific tumors using its Trimerbody® protein engineering technology. Trimerbody® is a registered trademark, fortified by international patents, exhibits higher multivalence and multispecificity compared to conventional immunoglobulins prevalent in the market. LeadArtis's drug candidates span multiple therapeutic areas, with a particular focus on immune-oncology.
These therapeutic proteins are based on specific antigen-binding domains and have unique structural and functional properties of naturally occurring collagen trimerization and through LeadArtis’s platform, they allow rapid generation and production of biological therapeutics.
Current Investors
Clave Capital, Sodena, Capital Cell Investors
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals
Website
www.leadartis.com/
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.